Olaparib: beside a new treatment under test
103 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 2. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07933419Phase 1/2Report a problem
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingNCT07652242Phase 1Report a problem
- A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingNCT07641855Phase 2/3Report a problem
- Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerNot yet recruitingNCT07637851Phase 1/2Report a problem
- Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian CancerNot yet recruitingNCT07550205Phase 2/3Report a problem
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07454018Phase 2Report a problem
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2Report a problem
- Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07407452Phase 2Report a problem
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingNCT07382544Phase 1Report a problem
- An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingNCT07371663Phase 1/2Report a problem
- The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and PaclitaxelNot yet recruitingNCT07187674Not applicableReport a problem
- Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid TumorsRecruitingNCT07156253Phase 1Report a problem
- QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)Not yet recruitingNCT07113964Phase 2Report a problem
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingNCT07024784Phase 2Report a problem
- Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2Report a problem
- Investigating Idetrexed and Olaparib in Patients With Ovarian CancerRecruitingNCT06976892Phase 1Report a problem
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3Report a problem
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT06915025Phase 3Report a problem
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingNCT06856499Phase 1Report a problem
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingNCT06797635Phase 2Report a problem
- Study of SIM0508 Alone and in Combination in Patients With Advanced Solid TumorsRecruitingNCT06686745Phase 1Report a problem
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2Report a problem
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06545942Phase 1Report a problem
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingNCT06488378Phase 1Report a problem
- Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian CancerRecruitingNCT06437353Phase 2Report a problem
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingNCT06298084Phase 1/2Report a problem
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2Report a problem
- Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)RecruitingNCT05898399Phase 1/2Report a problem
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingNCT04090567Phase 2Report a problem
- Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1Report a problem
- Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid TumorsTerminatedNCT06560632Phase 1Results postedReport a problem
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT05405309Phase 1/2Results postedReport a problem
- Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsTerminatedNCT04972110Phase 1/2Results postedReport a problem
- PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedNCT04556617Phase 1/2Results postedReport a problem
- Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results postedReport a problem
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT04034927Phase 2Results postedReport a problem
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingNCT03878095Phase 2Results postedReport a problem
- AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results postedReport a problem
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results postedReport a problem
- Study to Evaluate CCS1477 in Advanced TumoursCompletedNCT03568656Phase 1/2Results postedReport a problem
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerCompletedNCT03462342Phase 2Results postedReport a problem
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingNCT03330847Phase 2Results postedReport a problem
- Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibCompletedNCT03314740Phase 2Results postedReport a problem
- Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results postedReport a problem
- A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results postedReport a problem
- Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results postedReport a problem
- Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results postedReport a problem
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results postedReport a problem
- Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results postedReport a problem
- Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT02769962Phase 1/2Results postedReport a problem
- A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results postedReport a problem
- A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results postedReport a problem
- Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results postedReport a problem
- Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian CancerCompletedNCT07648745Phase 2Report a problem
- FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06909825Phase 2Report a problem
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)WithdrawnNCT06829199Phase 2Report a problem
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Active, not recruitingNCT06353386Phase 1/2Report a problem
- Study of SIM0501 Alone and in Combination in Patients With Advanced Solid TumorsTerminatedNCT06331559Phase 1Report a problem
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3Report a problem
- Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsTerminatedNCT06065059Phase 1/2Report a problem
- Study of LP-184 in Patients With Advanced Solid TumorsActive, not recruitingNCT05933265Phase 1/2Report a problem
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsActive, not recruitingNCT05932862Phase 1Report a problem
- Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1Report a problem
- Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid TumorsCompletedNCT05700669Phase 1/2Report a problem
- EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Phase 2Report a problem
- Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1Report a problem
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1Report a problem
- A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid TumorsCompletedNCT05240898Phase 1Report a problem
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1Report a problem
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT05005728Phase 2Report a problem
- A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian CancerTerminatedNCT04999605Phase 1/2Report a problem
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2Report a problem
- Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerActive, not recruitingNCT04742075Phase 2Report a problem
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedNCT04669002Phase 2Report a problem
- Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.TerminatedNCT04586335Phase 1Report a problem
- Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2Report a problem
- A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2Report a problem
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2Report a problem
- Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2Report a problem
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2Report a problem
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1Report a problem
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2Report a problem
- Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingNCT03641755Phase 1Report a problem
- ARQ761 + PARP Inhibitor in Refractory Solid TumorsWithdrawnNCT03575078Phase 1Report a problem
- Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2Report a problem
- Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]CompletedNCT03428607Phase 2Report a problem
- Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer PatientsStatus unknownNCT03278717Phase 3Report a problem
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1Report a problem
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2Report a problem
- Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsCompletedNCT03057145Phase 1Report a problem
- Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid TumorsStatus unknownNCT02684318Phase 1/2Report a problem
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicableReport a problem
- Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced CancerCompletedNCT02588105Phase 1Report a problem
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2Report a problem
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1Report a problem
- AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1Report a problem
- Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1Report a problem
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2Report a problem
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1Report a problem
- A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2Report a problem